New blood test could spot lung cancer mutations more accurately
NCT ID NCT06595498
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study tests a new, ultra-sensitive blood test (NGS) to detect EGFR gene mutations in patients with advanced lung cancer. Researchers will compare it to the current standard test using stored blood samples from 130 patients. The goal is to see if the new method finds more mutations, which could guide personalized treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Plasma-SeqSensei™ Solid Cancer IVD Kit (a blood test)
- What this could lead to
- If successful, this could provide a more sensitive blood test for lung cancer mutations, helping doctors choose better treatments without invasive biopsies.
- What could go wrong
- This is an early evaluation study, not a treatment trial. The new test may not prove more accurate than the current standard, and results may not change patient care immediately.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istituto Oncologico Veneto
Padova, 35128, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.